Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study

OBJECTIVES: This study investigated the effects of dose step-down in patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib 4 mg once a day. METHODS: Patients who completed a baricitinib phase 3 study could enter a long-term extension (LTE). In the LTE, patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Genovese, Mark C, Haraoui, Boulos, Li, Zhanguo, Xie, Li, Klar, Rena, Pinto-Correia, Ana, Otawa, Susan, Lopez-Romero, Pedro, de la Torre, Inmaculada, Macias, William, Rooney, Terence P, Smolen, Josef S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352419/
https://www.ncbi.nlm.nih.gov/pubmed/30194275
http://dx.doi.org/10.1136/annrheumdis-2018-213271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352419/
https://www.ncbi.nlm.nih.gov/pubmed/30194275
http://dx.doi.org/10.1136/annrheumdis-2018-213271

Ejemplares similares